July 24, 2017 07:04 AM EDTUpdated 07:19 AM
Deals

Mit­subishi Tan­abe bags Neu­ro­Derm and its PhI­II Parkin­son’s pro­gram for $1.1B

John Carroll

Editor & Founder

Mit­subishi Tan­abe is gob­bling up the Is­raeli biotech Neu­ro­Derm $NDRM, of­fer­ing an ear­ly morn­ing taste of the M&A ac­tiv­i­ty that has been woe­ful­ly short …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times